Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall

Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results from a Phase 3 trial on their mRNA-based shot after partial data leaked on social media platforms earlier that day.